NCT06053658 2026-04-14
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
15 trialsNCT06661720 2026-04-07
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT07218692 2025-10-20
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT01769885 2022-08-15
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT01853644 2021-10-12
TIVO
Northwestern University
Phase 2 Completed
NCT01835223 2020-10-28
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01782313 2019-09-09
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Northwestern University
Phase 2 Completed
NCT01846871 2019-01-08
Tivozanib for Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT01972516 2017-06-05
Tivozanib As Maintenance Therapy In GYN
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01058655 2017-04-13
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01807156 2016-04-22
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT01728181 2013-07-25
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
University of Utah
Phase 1/2 Withdrawn
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn